Literature DB >> 25119334

Transplantation of neural stem cells clonally derived from embryonic stem cells promotes recovery after murine spinal cord injury.

Ryan P Salewski1, Robert A Mitchell, Carl Shen, Michael G Fehlings.   

Abstract

The pathology of spinal cord injury (SCI) makes it appropriate for cell-based therapies. Treatments using neural stem cells (NSCs) in animal models of SCI have shown positive outcomes, although uncertainty remains regarding the optimal cell source. Pluripotent cell sources such as embryonic stem cells (ESCs) provide a limitless supply of therapeutic cells. NSCs derived using embryoid bodies (EB) from ESCs have shown tumorigenic potential. Clonal neurosphere generation is an alternative method to generate safer and more clinically relevant NSCs without the use of an EB stage for use in cell-based therapies. We generated clonally derived definitive NSCs (dNSCs) from ESC. These cells were transplanted into a mouse thoracic SCI model. Embryonic stem cell-derived definitive neural stem cell (ES-dNSC)-transplanted mice were compared with controls using behavioral measures and histopathological analysis of tissue. In addition, the role of remyelination in injury recovery was investigated using transmission electron microscopy. The SCI group that received ES-dNSC transplantation showed significant improvements in locomotor function compared with controls in open field and gait analysis. The cell treatment group had a significant enhancement of spared neural tissue. Immunohistological assessments showed that dNSCs differentiated primarily to oligodendrocytes. These cells were shown to express myelin basic protein, associate with axons, and support nodal architecture as well as display proper compact, multilayer myelination in electron microscopic analysis. This study provides strong evidence that dNSCs clonally derived from pluripotent cells using the default pathway of neuralization improve motor function after SCI and enhance sparing of neural tissue, while remaining safe and clinically relevant.

Entities:  

Mesh:

Year:  2015        PMID: 25119334      PMCID: PMC4273190          DOI: 10.1089/scd.2014.0096

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  65 in total

1.  Lineage-restricted neural precursors survive, migrate, and differentiate following transplantation into the injured adult spinal cord.

Authors:  A C Lepore; I Fischer
Journal:  Exp Neurol       Date:  2005-07       Impact factor: 5.330

2.  Transplantation of embryonic spinal cord-derived neurospheres support growth of supraspinal projections and functional recovery after spinal cord injury in the neonatal rat.

Authors:  M Nakamura; H Okano; Y Toyama; H N Dai; T P Finn; B S Bregman
Journal:  J Neurosci Res       Date:  2005-08-15       Impact factor: 4.164

3.  Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations.

Authors:  Birgit Neuhuber; B Timothy Himes; Jed S Shumsky; Gianluca Gallo; Itzhak Fischer
Journal:  Brain Res       Date:  2005-02-21       Impact factor: 3.252

4.  Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome.

Authors:  Christoph P Hofstetter; Niklas A V Holmström; Johan A Lilja; Petra Schweinhardt; Jinxia Hao; Christian Spenger; Zsuzsanna Wiesenfeld-Hallin; Shekar N Kurpad; Jonas Frisén; Lars Olson
Journal:  Nat Neurosci       Date:  2005-02-13       Impact factor: 24.884

5.  FGF-2 is sufficient to isolate progenitors found in the adult mammalian spinal cord.

Authors:  L S Shihabuddin; J Ray; F H Gage
Journal:  Exp Neurol       Date:  1997-12       Impact factor: 5.330

6.  Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice.

Authors:  Brian J Cummings; Nobuko Uchida; Stanley J Tamaki; Desirée L Salazar; Mitra Hooshmand; Robert Summers; Fred H Gage; Aileen J Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

7.  The intermediate filament cytoskeleton of myofibroblasts: an immunofluorescence and ultrastructural study.

Authors:  W Schürch; T A Seemayer; R Lagacé; G Gabbiani
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

8.  Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury.

Authors:  Hans S Keirstead; Gabriel Nistor; Giovanna Bernal; Minodora Totoiu; Frank Cloutier; Kelly Sharp; Oswald Steward
Journal:  J Neurosci       Date:  2005-05-11       Impact factor: 6.167

9.  Comparing deficits following excitotoxic and contusion injuries in the thoracic and lumbar spinal cord of the adult rat.

Authors:  D S Magnuson; T C Trinder; Y P Zhang; D Burke; D J Morassutti; C B Shields
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

10.  A mouse model of graded contusive spinal cord injury.

Authors:  P L Kuhn; J R Wrathall
Journal:  J Neurotrauma       Date:  1998-02       Impact factor: 5.269

View more
  27 in total

1.  Meta-analysis of stem cell transplantation for reflex hypersensitivity after spinal cord injury.

Authors:  Xuemei Chen; Bohan Xue; Yuping Li; Chunhua Song; Peijun Jia; Xiuhua Ren; Weidong Zang; Jian Wang
Journal:  Neuroscience       Date:  2017-06-27       Impact factor: 3.590

2.  Transplantation of Induced Pluripotent Stem Cell-Derived Neural Stem Cells Mediate Functional Recovery Following Thoracic Spinal Cord Injury Through Remyelination of Axons.

Authors:  Ryan P Salewski; Robert A Mitchell; Lijun Li; Carl Shen; Maria Milekovskaia; Andras Nagy; Michael G Fehlings
Journal:  Stem Cells Transl Med       Date:  2015-05-15       Impact factor: 6.940

Review 3.  Does the preclinical evidence for functional remyelination following myelinating cell engraftment into the injured spinal cord support progression to clinical trials?

Authors:  Scott A Myers; Andrew N Bankston; Darlene A Burke; Sujata Saraswat Ohri; Scott R Whittemore
Journal:  Exp Neurol       Date:  2016-04-13       Impact factor: 5.330

4.  Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.

Authors:  Yan-Hua Li; Jing-Wen Yu; Jian-Yin Xi; Wen-Bo Yu; Jian-Chun Liu; Qing Wang; Li-Juan Song; Ling Feng; Ya-Ping Yan; Guang-Xian Zhang; Bao-Guo Xiao; Cun-Gen Ma
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

Review 5.  Cell Therapeutic Strategies for Spinal Cord Injury.

Authors:  Pinghui Zhou; Jingjing Guan; Panpan Xu; Jingwen Zhao; Changchun Zhang; Bin Zhang; Yingji Mao; Wenguo Cui
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-10-16       Impact factor: 4.730

6.  A Comparative Study of Three Different Types of Stem Cells for Treatment of Rat Spinal Cord Injury.

Authors:  Jiri Ruzicka; Lucia Machova-Urdzikova; John Gillick; Takashi Amemori; Nataliya Romanyuk; Kristyna Karova; Kristyna Zaviskova; Jana Dubisova; Sarka Kubinova; Raj Murali; Eva Sykova; Meena Jhanwar-Uniyal; Pavla Jendelova
Journal:  Cell Transplant       Date:  2016-11-02       Impact factor: 4.064

Review 7.  Assessment and management of acute spinal cord injury: From point of injury to rehabilitation.

Authors:  Laureen D Hachem; Christopher S Ahuja; Michael G Fehlings
Journal:  J Spinal Cord Med       Date:  2017-06-01       Impact factor: 1.985

8.  miR-31 promotes neural stem cell proliferation and restores motor function after spinal cord injury.

Authors:  Xiao Li; Yuantao Gao; Feng Tian; Ruochen Du; Yitong Yuan; Pengfei Li; Fang Liu; Chunfang Wang
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-09

Review 9.  Corticospinal Motor Circuit Plasticity After Spinal Cord Injury: Harnessing Neuroplasticity to Improve Functional Outcomes.

Authors:  Syed Faraz Kazim; Christian A Bowers; Chad D Cole; Samantha Varela; Zafar Karimov; Erick Martinez; Jonathan V Ogulnick; Meic H Schmidt
Journal:  Mol Neurobiol       Date:  2021-08-03       Impact factor: 5.590

Review 10.  The Potential for iPS-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: Opportunities and Challenges.

Authors:  Mohamad Khazaei; Ahad M Siddiqui; Michael G Fehlings
Journal:  J Clin Med       Date:  2014-12-29       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.